{
    "Question": "Eclypia CES 2024 product highlight and specification",
    "Summary": "Eclypia\n\nNeogly\n\n- Non-invasive continuous glucose monitoring device\n- Built on photonics technologies\n- Life-changing innovation for people with diabetes\n- Multi-expertise approach tackling technological, physiological, and algorithmic challenges\n- Engineering expertise in optics, electronics, software, and mechanical components\n- Signal processing and artificial intelligence capabilities\n- Expertise in physiology, metabolism, endocrinology, and diabetes\n- Regulatory and compliance knowledge\n- General Manager: Hélène Lefebvre\n- CTO: Jean-Guillaume Coutard\n- Supported by BPI France through the PSPC R&D Program\n- Manages a portfolio of 30 patents\n- White paper available on real-life glycemia prediction algorithm development\n",
    "Summary_cn": "Eclypia\n\nNeogly\n\n- 非侵入性连续血糖监测设备\n- 基于光子技术构建\n- 对糖尿病患者来说是具有生命改变作用的创新\n- 多专业知识的方法解决技术、生理和算法挑战\n- 在光学、电子、软件和机械组件方面具有工程专长\n- 信号处理和人工智能能力\n- 生理学、代谢学、内分泌学和糖尿病领域的专业知识\n- 监管和合规知识\n- 总经理：Hélène Lefebvre\n- 首席技术官：Jean-Guillaume Coutard\n- 通过PSPC研发计划获得BPI France的支持\n- 管理着30项专利组合\n- 提供有关实际血糖预测算法开发的白皮书"
}